Eczema Trial, Recruiting (NCT07290803)

Eczema Trial, Recruiting NCT07290803 Sponsor: Sanofi Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT07290803 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are 12 years old or older at the time of giving consent to participate.
You have been diagnosed with atopic dermatitis (eczema) of any severity, confirmed by a doctor using standard medical guidelines.
You have been prescribed and are about to start a systemic (whole-body) treatment for your eczema, such as certain injections, pills, or other medicines that work throughout the body.
You (or your parent or legal guardian, if applicable) are willing to sign a consent form and take part in long-term follow-up visits.

Who may not be able to join:

You are currently taking part in another clinical trial that involves receiving an experimental drug that changes how your condition is managed.
You or your parent or guardian do not have a sufficient understanding of what the study involves (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 800-633-1610

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07290803

Sponsor: Sanofi

Phase: Not Applicable

Status: Recruiting

Condition: Eczema

Trial contact: 800-633-1610

More information: https://clinicaltrials.gov/study/NCT07290803

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are 12 years old or older at the time of giving consent to participate.
You have been diagnosed with atopic dermatitis (eczema) of any severity, confirmed by a doctor using standard medical guidelines.
You have been prescribed and are about to start a systemic (whole-body) treatment for your eczema, such as certain injections, pills, or other medicines that work throughout the body.
You (or your parent or legal guardian, if applicable) are willing to sign a consent form and take part in long-term follow-up visits.

Who may not be able to join:

You are currently taking part in another clinical trial that involves receiving an experimental drug that changes how your condition is managed.
You or your parent or guardian do not have a sufficient understanding of what the study involves (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Sanofi

Registry

ClinicalTrials.gov

Start date

17 November 2025

Est. completion

30 January 2034

Where this trial is recruiting

🇨🇦 Canada 🇨🇳 China 🇫🇷 France 🇮🇹 Italy 🇯🇵 Japan 🇸🇦 Saudi Arabia 🇦🇪 United Arab Emirates 🇺🇸 United States

Primary endpoints

Number of Participants Utilizing Atopic Dermatitis (AD) Treatment; Duration of Treatment; AD Treatment Sequences; Number of Participants Initiating AD Treatments with Reasons; Number of Participants Interrupting AD Treatment; Number of Participants Discontinuing AD Treatment; Number of Participants Switching AD Treatments; Number of Participants Augmenting AD treatment; Number of Participants Modifying AD Treatment Dose; Change from Baseline in Extent and Severity of AD Measured with Eczema Area and Severity Index (EASI); Change from Baseline in Extent and Severity of AD Measured with Body Sur...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov